Hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients 1. Aged less than 20years 2.Residents of Japan who received locoregional therapy for hepatocellular carcinoma (hepatectomy or ablation) more than two times 3.Within 5 years of last locoregional therapy (hepatectomy or ablation) 4.Signed informed consent form Physicians 1.Licensed Japanese medical doctors who performed an average of at least 5cases/year of hepatectomy or ablation within 5 years 2.At least five cases of hepatectomy or ablation in the last year 3.Signed informed consent form
Exclusion criteria
Exclusion criteria: Patients who are engaged in a pharmaceutical, medical, or survey-related job
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Well-being and the factors associated with well-being changes in patients with Early-stage hepatocellular carcinoma | — |
Secondary
| Measure | Time frame |
|---|---|
| To clarify the important things for patients in locoregional therapy and adjuvant therapy from the views of patients who received locoregional therapy and physicians who performed locoregional therapy, respectively. | — |
Countries
Japan
Contacts
3H Clinical Trial Co., Ltd. Insight & Outcome Group